Real-World data to reveal how new myeloma combo works outside trials
NCT ID NCT07532473
First seen Apr 20, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant. All patients received a combination of three drugs (daratumumab, lenalidomide, and dexamethasone) as their first treatment. The goal is to see how well this therapy works in everyday practice, including response rates and side effects, rather than in a controlled clinical trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Royal Wolverhampton NHS Trust
Wolverhampton, WV10 0QP, United Kingdom
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.